Novartis

Latest stories

3h
Market Watch
Biotech firm Intellia prices at top of IPO rangehas raised hopes for future drugs that could home in on specific genes and remo
Biotech firm Intellia prices at top of IPO range
Market Watch / Posted 3 hours ago
has raised hopes for future drugs that could home in on specific genes and remove them. The company's shareholders include Novartis AG, which participated in a $15 million Series A financing round and a $70 million Series B round, and Regeneron... Read more
16h
The Atlantic
How to Bet Big on the American Dreamprofessional training, followed by six months of interning at global companies
How to Bet Big on the American Dream
The Atlantic / Posted 16 hours ago
professional training, followed by six months of interning at global companies such as State Street, Salesforce.com, and Novartis. Walton took the information-technology track, interned at a venture-capital startup in Boston, and was voted class... Read more
18h
Investors Chronicle
New drugs revenue on the rise for Glaxoin the pipeline and prioritising toothpaste over life-changing medicines (in re
New drugs revenue on the rise for Glaxo
Investors Chronicle / Posted 18 hours ago
in the pipeline and prioritising toothpaste over life-changing medicines (in reference to the $20bn asset swap with Novartis), have been cited as key issues that reduce the value of the pharma giant. But outgoing chief executive Andrew Witty... Read more
18h
Business Wire
Bicycle Therapeutics Strengthens Product Development Capabilities with Key Leadership AppointmentsDevelopment Manager. She also served as Head of Gene Medicine Development at Ar
Bicycle Therapeutics Strengthens Product Development Capabilities with Key Leadership Appointments
Business Wire / Posted 18 hours ago
Development Manager. She also served as Head of Gene Medicine Development at Ark Therapeutics Ltd. While at Imutran Ltd, a Novartis Pharma AG company, she held the roles of Unit Head of Molecular Biology and Unit Head of Retroviral Research. Dr... Read more
18h
Business Standard India
Markets snap 3-day losing spell as oil, European stocks reboundPharma surged 1.3% amid reports that the pharma major is scouting for a partner
Markets snap 3-day losing spell as oil, European stocks rebound
Business Standard India / Posted 18 hours ago
Pharma surged 1.3% amid reports that the pharma major is scouting for a partner to market 14 brands it acquired from Novartis in Japan. Among others, Lupin, Dr Reddys’ Lab and Cipla gained between 0.2%-1.5%. Another prominent gainer was L&T... Read more
10 related stories
19h
Business Standard India
Markets gather pace; Sensex soars nearly 300 pointsPharma surged 1.7% amid reports that the pharma major is scouting for a partner
Markets gather pace; Sensex soars nearly 300 points
Business Standard India / Posted 19 hours ago
Pharma surged 1.7% amid reports that the pharma major is scouting for a partner to market 14 brands it acquired from Novartis in Japan. Among others, Lupin, Dr Reddys’ Lab and Cipla gained between 0.2%-1.5%. Larsen & Toubro Infotech (L&T... Read more
10 related stories
21h
Business Standard India
Sensex gains over 150 points; Nifty nears 7,750Pharma was up nearly 2% amid reports that the pharma major is scouting for a pa
Sensex gains over 150 points; Nifty nears 7,750
Business Standard India / Posted 21 hours ago
Pharma was up nearly 2% amid reports that the pharma major is scouting for a partner to market 14 brands it acquired from Novartis in Japan. Among others Lupin was up 1.8%. Larsen & Toubro Infotech (L&T Infotech), IT services & solutions... Read more
10 related stories
1d
Business Standard India
Flat-to-negative opening seen as Asian stocks remain weaklargest pharmaceutical firm, Sun Pharmaceutical, is scouting for a partner to m
Flat-to-negative opening seen as Asian stocks remain weak
Business Standard India / Posted yesterday
largest pharmaceutical firm, Sun Pharmaceutical, is scouting for a partner to market 14 brands it acquired from Novartis in Japan. NTPC has issued a notice for non-payment to Reliance Infrastructure’s two electricity distribution... Read more
1d
Business Standard India
Sun looks for partner in JapanIndia’s largest pharmaceutical firm, Sun Pharmaceutical, is scouting for a part
Sun looks for partner in Japan
Business Standard India / Posted yesterday
India’s largest pharmaceutical firm, Sun Pharmaceutical, is scouting for a partner to market 14 brands it acquired from Novartis in Japan. “We are looking for a partner to market these brands there. The decision regarding this would be taken in... Read more
3 related stories
1d
The New Zealand Herald
The blues singer who created the US hated drug pricing modelhelped launch one of the first first super high-priced drugs a year after he we
The blues singer who created the US hated drug pricing model
The New Zealand Herald / Posted yesterday
helped launch one of the first first super high-priced drugs a year after he went to work at Sandoz, now part of Novartis, in 1988. The antipsychotic Clozaril retailed for nearly $9,000 a year; previous treatments went for hundreds.... Read more
1d
New Kerala
Telangana seeks Malaysia's cooperation to set up industrial parks - newkerala.com #58881acres of land for setting up new industrial units. He told the visiting delega
Telangana seeks Malaysia's cooperation to set up industrial parks - newkerala.com #58881
New Kerala / Posted yesterday
acres of land for setting up new industrial units. He told the visiting delegations that Amazon, Google, Microsoft and Novartis have set up their campuses in Hyderabad. The Malaysian minister assured that his government would work closely with... Read more
2d
FOX Business
What Sent Medivation, Inc.'s Shares Soaring 25.1% In Aprilwill want to buy Medivation itself to gain 100% rights to this drug. Other com
What Sent Medivation, Inc.'s Shares Soaring 25.1% In April
FOX Business / Posted 2 days ago
will want to buy Medivation itself to gain 100% rights to this drug. Other companies, including Gilead Sciences and Novartis have expressed an interest in expanding their oncology product portfolios. And, AbbVie, has been on the hunt... Read more
15 related stories
2d
FOX Business
What Sent Medivation, Inc.'s Shares Soaring 25.1% In Aprilwill want to buy Medivation itself to gain 100% rights to this drug. Other com
What Sent Medivation, Inc.'s Shares Soaring 25.1% In April
FOX Business / Posted 2 days ago
will want to buy Medivation itself to gain 100% rights to this drug. Other companies, including Gilead Sciences and Novartis have expressed an interest in expanding their oncology product portfolios. And, AbbVie, has been on the hunt... Read more
15 related stories
2d
News-Medical-Net
New investigational inhibitor JQEZ5 can block specific molecular malfunctions driving cancerCancer Institute, and James E. Bradner, MD, formerly of the Dana-Farber Cancer
New investigational inhibitor JQEZ5 can block specific molecular malfunctions driving cancer
News-Medical-Net / Posted 2 days ago
Cancer Institute, and James E. Bradner, MD, formerly of the Dana-Farber Cancer Institute and now president of the Novartis Institutes for BioMedical Research, was highly potent in animal models of EZH2-mutant cancer. The authors showed... Read more
2d
The Economic Times
US watch list may hit affordable drug businessintense US scrutiny of the Indian judiciary of its handling of patent disputes
US watch list may hit affordable drug business
The Economic Times / Posted 2 days ago
intense US scrutiny of the Indian judiciary of its handling of patent disputes including its decisions on patentability (Novartis vs. Union of India), compulsory licensing (Bayer Corporation vs. Union of India), and finally on any failure to... Read more
3d
TheStreet.com
This undervalued big pharma stock hit bottom and is ready to break outits low PEG ratio, the stock is incredibly undervalued compared with peers such
This undervalued big pharma stock hit bottom and is ready to break out
TheStreet.com / Posted 3 days ago
its low PEG ratio, the stock is incredibly undervalued compared with peers such as J&J (2.98), Merck (3.02) and Novartis (2.82). "I have enjoyed 1,586 days of free money." If big, triple-digit winners get your adrenaline pumping, then... Read more
3 related stories
3d
TheStreet.com
Should you place an early bet on the ipo of gene-splicing pioneer intellia?it has received votes of confidence -- and funding -- from two well-known large
Should you place an early bet on the ipo of gene-splicing pioneer intellia?
TheStreet.com / Posted 3 days ago
it has received votes of confidence -- and funding -- from two well-known large-cap pharmaceutical companies: Regeneron and Novartis. Meanwhile, Intellia last month revealed a partnership with Novartis that will provide $63 million in upfront and... Read more
3d
TheStreet.com
2 dirt-cheap big pharma stocks poised to beat biotech's bad rapcheap right now. Let's take a closer look at why these unloved stocks belong in
2 dirt-cheap big pharma stocks poised to beat biotech's bad rap
TheStreet.com / Posted 3 days ago
cheap right now. Let's take a closer look at why these unloved stocks belong in your growth portfolio. Switzerland-based Novartis may face falling revenue and earnings over the short term, amid patent expirations and lackluster sales of some... Read more
3d
FOX Business
The Single Most Important Thing About GlaxoSmithKline's Q1 Reporteffort to improve efficiency and its operating margin. The most recent of those
The Single Most Important Thing About GlaxoSmithKline's Q1 Report
FOX Business / Posted 3 days ago
effort to improve efficiency and its operating margin. The most recent of those efforts involves cost synergies tied to its Novartis deal that closed last year. Image source: GlaxoSmithKline. GSK's and Novartis' asset swap was a three-pronged... Read more
3d
FOX Business
The Single Most Important Thing About GlaxoSmithKline's Q1 Reporteffort to improve efficiency and its operating margin. The most recent of those
The Single Most Important Thing About GlaxoSmithKline's Q1 Report
FOX Business / Posted 3 days ago
effort to improve efficiency and its operating margin. The most recent of those efforts involves cost synergies tied to its Novartis deal that closed last year. Image source: GlaxoSmithKline. GSK's and Novartis' asset swap was a three-pronged... Read more
3d
Business Wire
Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopeniainfusion. Nplate® is a registered trademark of Amgen, Inc. and Promacta®/Revol
Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia
Business Wire / Posted 3 days ago
infusion. Nplate® is a registered trademark of Amgen, Inc. and Promacta®/Revolade™ are registered trademarks of Novartis AG. About Protalex, Inc. Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development... Read more
3d
Business Wire
AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAHthe results is being prepared for submission to a peer-reviewed journal. “Like
AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
Business Wire / Posted 3 days ago
the results is being prepared for submission to a peer-reviewed journal. “Like AV-380 in cachexia, which AVEO licensed to Novartis in 2015, AV-353 is an AVEO legacy discovery program that, with the appropriate development support from a partner,... Read more
4d
Philly.com
Fighting to tame metastatic breast cancerof metastatic patient groups, traditional breast cancer nonprofits, research fo
Fighting to tame metastatic breast cancer
Philly.com / Posted 4 days ago
of metastatic patient groups, traditional breast cancer nonprofits, research foundations, and drug companies including Novartis, Eli Lilly, and Celgene. In an exhaustive 2014 report, the alliance decried "a lack of awareness about metastatic... Read more
5d
Boston Globe
Walsh, as union leader, worked to bridge gap between developers, unionsin January 2011, he was thrust into the middle of virtually every major constru
Walsh, as union leader, worked to bridge gap between developers, unions
Boston Globe / Posted 5 days ago
in January 2011, he was thrust into the middle of virtually every major construction project in the region, from the Novartis Pharmaceuticals headquarters in Cambridge to the redevelopment of the Old Colony housing complex in South... Read more
4 related stories
5d
News-Medical-Net
Early exposure to pathogens may play pivotal role in immune system developmentof an extensive collaboration involving researchers at Aalto University, Broad
Early exposure to pathogens may play pivotal role in immune system development
News-Medical-Net / Posted 5 days ago
of an extensive collaboration involving researchers at Aalto University, Broad Institute, University of Helsinki, the Novartis Institute of Biomedical Research, and other organizations across the globe working together as part of the... Read more
6d
Daily Mail
Google patents vision correcting gadget implanted into your EYEBALLonto the eye’s retina. Google is also developing smart lenses for diabetics, a
Google patents vision correcting gadget implanted into your EYEBALL
Daily Mail / Posted 6 days ago
onto the eye’s retina. Google is also developing smart lenses for diabetics, and last year signed a deal with health giant Novartis to produce its groundbreaking smart contact lenses. RELATED ARTICLES Has the Midlands Meteorite been found in... Read more
9 related stories
6d
Engadget
Google patents smart lenses you inject into your eyesa wearer's glucose levels. That patent moved closer to becoming a reality when
Google patents smart lenses you inject into your eyes
Engadget / Posted 6 days ago
a wearer's glucose levels. That patent moved closer to becoming a reality when Google partnered with healthcare company Novartis to help develop the technology. As for the competition, Sony has also jumped into the game with a patent for a smart... Read more
9 related stories
6d
Market Watch
AstraZeneca's investment eats into profitin 2015, could generate $45 billion in revenue by 2023. By comparison, the worl
AstraZeneca's investment eats into profit
Market Watch / Posted 6 days ago
in 2015, could generate $45 billion in revenue by 2023. By comparison, the world's three largest drugmakers -- Pfizer Inc., Novartis AG and Roche Holding AG -- posted sales of around $50 billion in 2015. That promise was a key plank in his defense... Read more
3 related stories
6d
Business Standard India
NPPA caps prices of another 50 drugsIndia. Sun Pharmaceutical has about 19 per cent share. Xylometazoline, a coug
NPPA caps prices of another 50 drugs
Business Standard India / Posted 6 days ago
India. Sun Pharmaceutical has about 19 per cent share. Xylometazoline, a cough medicine where the market is dominated by Novartis (85-95 per cent market share), saw its price capped as well. Anti-constipation drug Lactulose, which has annual... Read more
6d
Swissinfo
AstraZeneca, Pfizer Said Among Firms Weighing Medivation Bidfor Medivation Inc., challenging Sanofi’s $9.3 billion bid for the company, peo
AstraZeneca, Pfizer Said Among Firms Weighing Medivation Bid
Swissinfo / Posted 6 days ago
for Medivation Inc., challenging Sanofi’s $9.3 billion bid for the company, people familiar with the matter said. Novartis AG is also exploring a bid, said people familiar with the matter. The Basel, Switzerland-based firm, along with... Read more
31 related stories
6d
NJ Biz
U.K. pharma firm cuts ribbon on new U.S. HQ in Landingto the company’s vice president of U.S. operations, Lucas Nigro. Nigro is a ph
U.K. pharma firm cuts ribbon on new U.S. HQ in Landing
NJ Biz / Posted 6 days ago
to the company’s vice president of U.S. operations, Lucas Nigro. Nigro is a pharma veteran who has previously worked at Novartis and Stryker. Currently, BAP has about five to 10 clients in New Jersey, Nigro said. To provide services to those... Read more
6d
Business Standard India
NPPA caps prices of 50 new drugsdrug's market with about 19 per cent share. Xylometazoline, a cough medicine w
NPPA caps prices of 50 new drugs
Business Standard India / Posted 6 days ago
drug's market with about 19 per cent share. Xylometazoline, a cough medicine where the market is completely dominated by Novartis (85-95 per cent market share), saw its price capped as well. Anti-constipation drug Lactulose, which has annual... Read more
6d
International Business Times
Massive security flaw found in Microsoft Office 365 leaving world's largest companies exposed Fund, The Daily Mail, Telefonica, Toyota Motors North America, Pricewaterhouse
Massive security flaw found in Microsoft Office 365 leaving world's largest companies exposed
International Business Times / Posted 6 days ago
Fund, The Daily Mail, Telefonica, Toyota Motors North America, Pricewaterhouse Coopers (PwC), KPMG, Verizon, Vodafone, Novartis Pharma AG, Japan Airlines, Caltex Australia, City of Chicago, British Airways, Royal Dutch Shell, British Airways,... Read more
6d
Market Watch
AstraZeneca investment eats into profitin 2015, could generate $45 billion in revenue by 2023. By comparison, the worl
AstraZeneca investment eats into profit
Market Watch / Posted 6 days ago
in 2015, could generate $45 billion in revenue by 2023. By comparison, the world's three largest drugmakers-- Pfizer Inc., Novartis AG and Roche Holding AG--posted sales of around $50 billion in 2015. That promise was a key plank in his defense... Read more
3 related stories
6d
Market Watch
AstraZeneca investment eats into profitin 2015, could generate $45 billion in revenue by 2023. By comparison, the worl
AstraZeneca investment eats into profit
Market Watch / Posted 6 days ago
in 2015, could generate $45 billion in revenue by 2023. By comparison, the world's three largest drugmakers--Pfizer Inc., Novartis AG and Roche Holding AG--posted sales of around $50 billion in 2015. That promise was a key plank in his defense... Read more
3 related stories
7d
FOX Business
Sanofi's Bid for Medivation Is Too Lowmedicine is massive, and it's growing as aging baby boomers live longer. That f
Sanofi's Bid for Medivation Is Too Low
FOX Business / Posted 7 days ago
medicine is massive, and it's growing as aging baby boomers live longer. That fact has everyone from Gilead Sciences to Novartis angling for market share. Given Medivation already markets a global top-seller, it's already profitable, and it has... Read more
31 related stories
7d
FOX Business
Sanofi's Bid for Medivation Is Too Lowmedicine is massive, and it's growing as aging baby boomers live longer. That f
Sanofi's Bid for Medivation Is Too Low
FOX Business / Posted 7 days ago
medicine is massive, and it's growing as aging baby boomers live longer. That fact has everyone from Gilead Sciences to Novartis angling for market share. Given Medivation already markets a global top-seller, it's already profitable, and it has... Read more
31 related stories
7d
Swissinfo
Colombian minister proposes ending Novartis patentof swissinfo.ch. In particular, any sale or commercial use of these data is pro
Colombian minister proposes ending Novartis patent
Swissinfo / Posted 7 days ago
of swissinfo.ch. In particular, any sale or commercial use of these data is prohibited. Anand Chandrasekhar Apr 28, 2016 - 15:19 The Colombian Health Minister Alejandro Gaviria has announced that... Read more
7d
Business Wire
Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusettsdemonstrated commitment to RNAi therapeutics has enabled it to form major allia
Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusetts
Business Wire / Posted 7 days ago
demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Ionis, Novartis, Roche, Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity... Read more
7d
Swissinfo
SNB's Mr Seven-Percent Stays Shy as Shareholders Meet in BernBrussels over a wave of immigration, many big companies have foreign executives
SNB's Mr Seven-Percent Stays Shy as Shareholders Meet in Bern
Swissinfo / Posted 7 days ago
Brussels over a wave of immigration, many big companies have foreign executives. Pharmaceutical giants Roche Holding AG and Novartis AG both have German chairmen. The SNB’s annual general meeting in Bern’s Kulturcasino starts at 10 a.m. and will... Read more
8d
heraldscotland
GlaxoSmithKline bolsters profits by nearly one-fifthsaw full-year core operating profit slump 13% to £5.73 billion in February afte
GlaxoSmithKline bolsters profits by nearly one-fifth
heraldscotland / Posted 8 days ago
saw full-year core operating profit slump 13% to £5.73 billion in February after a series of asset swaps with Swiss rival Novartis. The company is also on the hunt for a new chief executive after Sir Andrew Witty announced he will retire on March... Read more
8d
FOX News
UBS, MPM team up on $471M cancer fund to speed drug developmenton funding health-care startups, including a venture fund it closed last year a
UBS, MPM team up on $471M cancer fund to speed drug development
FOX News / Posted 8 days ago
on funding health-care startups, including a venture fund it closed last year at $400 million that included Swiss drugmaker Novartis and France's Astellas Pharma as investors. Investors in the new UBS fund have agreed not to withdraw their money... Read more
8d
The Charleston State Journal
2016 Bioscience Summit warned state research dollars drying upday, and offered a preview of new lens products now in development. She told S
2016 Bioscience Summit warned state research dollars drying up
The Charleston State Journal / Posted 8 days ago
day, and offered a preview of new lens products now in development. She told Summit attendees that Alcon’s parent company, Novartis, is now partnering with Google in perfecting an autofocus lens for patients with presbyopia (the loss of the eyes’... Read more
8d
Channel NewsAsia
GlaxoSmithKline rebound gathering pace, says outgoing CEOin its non-prescription operation, which was recently expanded through a US$20
GlaxoSmithKline rebound gathering pace, says outgoing CEO
Channel NewsAsia / Posted 8 days ago
in its non-prescription operation, which was recently expanded through a US$20 billion three-way asset swap with Novartis . "A rebound has started, if measured from the rather deep hole that had been dug," said Bernstein analyst Tim... Read more
6 related stories
8d
Channel NewsAsia
UBS, MPM team up on US$471 million cancer fund to speed drug developmentfunding health-care startups, including a venture fund it closed last year at U
UBS, MPM team up on US$471 million cancer fund to speed drug development
Channel NewsAsia / Posted 8 days ago
funding health-care startups, including a venture fund it closed last year at US$400 million that included Swiss drugmaker Novartis and France's Astellas Pharma as investors. Investors in the new UBS fund have agreed not to withdraw their money... Read more
8d
Channel NewsAsia
Higher margins and new drugs help GlaxoSmithKline beat forecastsin its non-prescription business, which was recently expanded through a US$20 b
Higher margins and new drugs help GlaxoSmithKline beat forecasts
Channel NewsAsia / Posted 8 days ago
in its non-prescription business, which was recently expanded through a US$20 billion three-way asset swap with Novartis . "This puts us on the right track to achieve the expectations we set out last year, although inevitably, we expect... Read more
6 related stories
8d
Belfast Telegraph
GlaxoSmithKline bolsters profits by nearly a fifthsaw full-year core operating profit slump 13% to £5.73 billion in February afte
GlaxoSmithKline bolsters profits by nearly a fifth
Belfast Telegraph / Posted 8 days ago
saw full-year core operating profit slump 13% to £5.73 billion in February after a series of asset swaps with Swiss rival Novartis. The company is also on the hunt for a new chief executive after Sir Andrew Witty announced he will retire on March... Read more
8d
Market Watch
GlaxoSmithKline profit falls after Novartis dealthe first quarter due to a tough year-earlier comparison, which was boosted by
GlaxoSmithKline profit falls after Novartis deal
Market Watch / Posted 8 days ago
the first quarter due to a tough year-earlier comparison, which was boosted by proceeds from its three-way transaction with Novartis AG; taking out that effect, profit rose--partly due to cost savings from the same deal. The U.K.-based... Read more
8d
Morningstar
Recent Drug Launches Buoy Bayer's Growthkidney disease and not heart failure is a good strategic move to reduce develop
Recent Drug Launches Buoy Bayer's Growth
Morningstar / Posted 8 days ago
kidney disease and not heart failure is a good strategic move to reduce development expenses; the recent approval of Novartis' heart failure drug Entresto creates a higher hurdle for efficacy in this indication. Also, Bayer is now looking for... Read more
8d
Irish Examiner
New approved drug will 'transform' lives of 100,000 living with heart failureheart failure are not controlled by the commonly used drugs, ACE inhibitors or
New approved drug will 'transform' lives of 100,000 living with heart failure
Irish Examiner / Posted 8 days ago
heart failure are not controlled by the commonly used drugs, ACE inhibitors or ARBs. Sacubitril valsartan, manufactured by Novartis, is the first of a new kind of drug. It works by widening the blood vessels and increasing blood flow while reducing... Read more
20 related stories
More

People in this news